This Cancer-Fighting Company Is In A Class Of Its Own

Genia Turanova's picture

Thursday, April 12, 2018 - 2:30pm

by Genia Turanova

There are few words in the English language that are hated more than "cancer." And as far as public health dangers go, it's one of the biggest enemies anyone could imagine. 

According to the World Health Organization (WHO), cancer is one of the leading causes of mortality in the world -- it's responsible for nearly 1 in 6 deaths. And the danger isn't going away anytime soon -- the WHO estimates that the number of cases in total will grow by 70% over the next two decades.

The sheer size of the threat also means the amount of brainpower and money the problem attracts will also be huge. Big pharma and smaller biotech companies alike have made it their business to find a cure -- or at least the best treatment when the cure has remained out of reach. This area of medicine has seen significant breakthroughs over the past several decades, and more are on the horizon. 

The Future Of Cancer-Fighting Medicines
One of the breakthroughs that have changed the approach to cancer treatment -- and can be credited with saving many lives -- is immunotherapy. 

With this approach, the patient's own immune system is utilized to attack cancerous cells by either helping the body better recognize the danger, or by assisting the cells in their cancer-fighting response. While traditional chemotherapy may be nonspecific, antibodies specifically target tumor-associated proteins, such as those found on the surface of tumor cells.

While immunotherapy has definitely been a revolutionary advance in science and medicine, it has not been the panacea some had hoped for. For one, it's not a cure. Further, this approach works better for some types of cancers than for others. Merck's (NYSE: MRK) cancer treatment Keytruda, for instance, is FDA-approved for specific forms and stages of melanoma, lung cancer, neck cancer, classical Hodgkin Lymphoma and a few more -- a lot, but still not a universal cure. Sales of Keytruda, however, exceeded $1.3 billion in the fourth quarter of 2017 (Some missteps from Merck's closest competitor, Bristol-Myers Squibb (NYSE: BMY), helped too.)

The pick I'm recommending to my Game-Changing Stocks subscribers is a much smaller company than either MRK or BMY. It's also more narrowly focused -- cancer is its specialty -- and its medicines use a different approach. While Merck's and Bristol-Myers' best-selling cancer drugs belong to the so-called checkpoint inhibitor class (drugs that help the immune system recognize and attack cancer cells), this company's immunotherapies belong to an entirely different class.

These medications are next-generation, targeted, antibody-based therapies. Treating cancer with antibody therapies is a promising approach because man-made antibodies are designed to attack a very specific part of a cancer cell, which means they can be effective for many different types of cancer.

Currently, the company has one approved drug. Designed to treat Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma (sALCL), the drug is already a success and is sold in more than 65 countries. And the company has more on the way, each tailored to one of the most common scourges in the cancer world -- like lymphoma, leukemia, urothelial (bladder) and breast cancer.

The company believes that its technologies are likely to be the future of treatment in oncology. And based on what I've seen, I have to agree. Now is the time to become positioned for the future with this exciting game-changing biotech stock.

I can't share the name of this particular pick with you today (that wouldn't be fair to my premium subscribers). But make no mistake: This is a game-changing field of business that could make investors a lot of money. If you do your homework and invest in the right player, you could wind up winning big.

P.S. The pharmaceutical field is just one of many areas my subscribers and I are finding opportunities for outsized gains in the market. From groundbreaking consumer products to wildly popular technology platforms -- we leave no stone unturned in Game-Changing Stocks. If you'd like to get the name and ticker symbol of my latest pick (along with access to the entire portfolio), then go here to learn more.

Genia Turanova does not personally hold positions in any securities mentioned in this article.
StreetAuthority LLC does not hold positions in any securities mentioned in this article.